Berberine-Pretreated Bone Marrow Mesenchymal Stem Cells Accelerate Skin Wound Healing in Rats With Burn Injuries.

Authors

Jinglei Tan, Caiqiang Chen

Published in

International wound journal. Volume 23. Issue 9. Pages e71029.

Abstract

Berberine (BBR) is a natural isoquinoline alkaloid with antibacterial, anti-inflammatory and pro-angiogenic properties. This study aimed to investigate the therapeutic efficacy and underlying mechanism of a conditioned medium (CM) derived from berberine-preconditioned bone marrow-derived mesenchymal stem cells (BMSCs-BBR). BMSCs were isolated and phenotypically characterised by flow cytometry. A burn wound model was established in Wistar rats, and the model rats were randomly allocated to four groups treated with placebo gel, standard BMSCs-CM gel, BMSCs-BBR CM gel, or silver sulfadiazine cream. Wound healing rates were monitored macroscopically. On Day 21, skin tissues were harvested for histological analysis (H&E and Masson's trichrome staining), followed by immunofluorescence staining (CD31) and Western blot analysis (Collagen I, Collagen III and key proteins in the PI3K/AKT/eNOS signalling pathway). Among all treatments, BMSCs-BBR CM accelerated wound closure the most significantly, accompanied by improved epidermal regeneration, enhanced collagen deposition and organisation and a marked increase in capillary density. Furthermore, wounds treated with BMSCs-BBR CM exhibited notably upregulated Collagen I and Collagen III, and activation of the PI3K/AKT/eNOS pathway, as evidenced by increased phosphorylation of PI3K and AKT and elevated eNOS protein levels. Our findings demonstrate that the topical application of BMSCs-BBR CM gel potently promotes burn wound healing by improving the quality of tissue regeneration and stimulating angiogenesis via the activation of the PI3K/AKT/eNOS signalling pathway. This preconditioning strategy represents a promising acellular therapeutic approach for burn wound management.

PMID:
42702357
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.